Game-changer for kidney disease: Novartis’ Fabhalta wins FDA approval in record time
Novartis has reached a pivotal moment in the treatment of rare kidney diseases with the US Food and Drug Administration (FDA) granting accelerated approval for ... Read More
Sobi and Apellis Pharmaceuticals report promising results for pegcetacoplan in phase 2 NOBLE study
Sobi and Apellis Pharmaceuticals, Inc. have announced encouraging one-year outcomes from the phase 2 NOBLE study, investigating the efficacy of systemic pegcetacoplan for treating post-transplant ... Read More
Positive results for pegcetacoplan in C3 glomerulopathy treatment: A step forward in kidney disease research
Apellis Pharmaceuticals has unveiled significant findings from its Phase 2 DISCOVERY clinical trial, offering a ray of hope for patients suffering from C3 glomerulopathy (C3G), ... Read More